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~-3 is a monoclonal antibody that recognizes a 
135,000 molecular weight structural component of ma-
turing keratinocytes in psoriasis (the 'lt-3 antigen) but 
fails to bind to any constituent of keratinocytes in nor-
mal epidermis. This paper describes the occurrence of 
the ~-3 antigen in a variety of dermatopathologic con-
ditions using immunoperoxidase (biotin-avidin-peroxi-
dase) and immunofluorescence methods which show ex-
cellent concordance. 
In 35 of 36 specimens of psoriasis vulgaris, 'lt-3 anti-
body consistently immunolabels the cytoplasm of kerat-
inocytes above the basal layer. At the edges of psoriatic 
plaques, 'lt-3 antibody staining extends for a variable 
distance into lesion-free epidermis. A similar pattern 
has been found in a certain number of other conditions 
described in the paper, including squamous cell carci-
noma and condyloma acuminatum, but not Darier's dis-
ease, basal cell carcinoma, nor lamellar ichthyosis. In 
all but one condition, the outermost or basal layer of 
cells is never stained. The only disease in which the 
lowermost cell layer is stained is a lichen planus-like 
lesion. 
The occurrence of ~-3 antigen cannot be correlated 
with any histologic feature of psoriasis such as acan-
thosis, loss of the granular layer, or hyperproliferation. 
The antigen appears to be a unique keratinocyte con-
stituent which is expressed in certain pathologic condi-
tions and which is not detected by any other histologic 
or immunophenotyping method. It is a potentially valu-
able addition to the panel of antibodies available for 
characterizing epithelial cells. 
With the development of antibodies capable of reacting spe-
cifically with a variety of cellular components, a widely appli-
cable immunophenotyping system, analogous to that available 
for lymphocytes [1-5], is developing [6-9]. The expression of 
intermediate filament classes has been found to be character-
istic of the tissue of origin of a tumor in a number of cases and 
has been used for recognition of metastases [9- 11]. In t he case 
of the lymphocyte immunophenotyping antibodies, it has been 
found that the use of a panel of antibodies provides a great deal 
more diagnostic information than the use of one or a small 
number [12- 14). App lying similar reasoning, it would be valu-
able to extend the range of markers availab le for typing non-
lymphoid tissues. 
The W-3 antibody, which was selected on the basis of its 
ability to stain psoriatic but not normal epidermis, binds to a 
triton-insoluble component of keratinocytes in certain experi-
mental and dermatologic lesions [15] . The range of conditions 
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does not correlate with any single histologic characteristic. The 
antibody appears to define a unique feature in the keratinocyte 
response to certain pathologic conditions. It may, thus, be a 
valuable addition to the array of antibodies reacting with the 
different keratins [16- 19) and other structural components. 
The study described in this paper was undertaken to charac-
terize the range of benign and malignant dermatologic condi-
tions under which t he W-3 antigen is expressed. 
MATERIALS AND METHODS 
Patients adm itted for psoriasis care and treatment of other cuta-
neous djseases to the Stanford University Hospital Outpatient Clinics 
and the Palo Alto Veterans Administration Hospital Outpatient Clinics 
comprised the patient population studied. The clinical criteria used to 
confirm the diagnosis of psoriasis included: (1) an established record 
of cutaneous plaques clinically suggestive of psoriasis; (2) bilateral 
sym metry of lesions; (3) involvement of characteristic skin sites; (4) 
presence of accompanying nail changes; (5) family history of psoriasis. 
Specimens accepted from patients meeting the above clinical criteria 
represented samples of plaques from many wfferent body locations. 
Within 15 min after biopsy removal, each specimen was mounted in 
Tissue-Tek (Miles Laboratories, Naperville, Illinois) and slowly frozen 
with Quik-Freeze (American Scientific Products, Sunnyvale, Cali for-
nia). Fifty to 100 consecutive 4- to 6-,.,m sections of each specimen 
were cut. The frozen sections were applied to coated (0.5% gelatin and 
0.05% KCr(SO,)z -12 H20) glass slides and stored at -7o·c. Consecu-
tive 4- to 6-J.Lm sections were used to ensure histologic ident ity between 
controls and tested sections. The method of immunofluorescence has 
been described previously (15]. 
For immunoperoxidase staining by the avidin -biotin-peroxidase 
method [20- 24], the tissue sections selected for study and consecutive 
control sections (previously stored at -70. C) were thawed, dried, fixed 
in cold acetone (-20 . C) for 10 min and endogenous peroxidase-reduced 
by incubation with 0.3% hydrogen peroxide. Sections were incubated 
successively with nonimmune serum (undiluted horse serum, GIBCO, 
Grand Island, New York) for 30 min, 60 nanonormal 'i'-3 antibody, 
biotinylated goat ant1mouse lgM (Cappel Laboratories, Cochranvi lle, 
Pennsylvania), 5 J.Lg/ml, and with aviwn-conjugated peroxidase (Vector 
Laboratories, Burlingame, California), 93 l'g/ml. All dilutions were 
made with 1% horse serum in phosphate-buffered saljne (PBS) . All 
incubations were of 1-h length at room temperature in a humidjtied 
chamber. Two 15-min PBS washes followed each incubation. The 
peroxidase reaction was developed in fresh ly made 3,3' -dimethylamino-
benzidine (Sigma Chemical Company, St. Louis, Missouri) , 1 mg/ml, 
in 0.3% hydrogen peroxide in PBS and filtered th rough a 0.2-J.Lm 
Millipore filter. After 15 min, the sections were washed thoroughly in 
distilled water and counterstained for 45 s in hematoxylin. F inally, all 
sections were dehydrated in graded alcohols, cleared in xylene, and 
mounted in Permount. 
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The 'it-3 antibody was origi nally selected on its ability to stain 
psoriatic but not normal epidermis (immunofluorescence and immu-
noperoxidase techniques). It is an IgM. Supernatant from 'i'-3 hybri-
doma cultures grown in 0.5% horse serum, concentrated by ammonium 
sulfate precipitation, gave a single precipitin line with antimouse lgM 
in Ouchterlony double diffusion plates [25 ]. No lines were observed in 
control wells containing horse serum a lone. The hybridoma producing 
'it-3 antibody has been recloned 3 times and there has been no change 
detected in immunoreactivity among different lots. 
In controls for the studies described below, we have found no staining 
of normal epidermis in 16 specimens from nonpsoriatic individuals nor 
in 10 biopsies taken at least 2 em away from psoriatic lesions. No IJt -3-
like staining has been observed in experiments where psoriatic skin 
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has been treated with supernatants from hybridomas which did not 
produce "'-3 antibody. 
basal layer staining in this condition could be accounted for by 
melanin granules. This conclusion that \lt-3 does not stain the 
basal cells was confirmed by examination of companion sec-
tions stained by immunofluorescence methods (data not 
shown). 
Tissue sections fixed in formalin, glutaraldehyde, or methanol could 
not be stained by 'I1 ·3, demonstrating the instability of the "'-3 antigen 
in these solvents. 
RESULTS 
Histopathologic Survey 
Table I lists the cutaneous diseases surveyed and stained by 
immunoperoxidase techniques with \lt-3 monoclonal antibody. 
Psoriasis Vulgaris 
We have studied 36 patients with typical psoriatic plaques of 
which 35 showed staining with w-3 antibody. The biopsy shown 
in Fig la-c was taken from the margin of a well-established 
plaque of an untreated patient. Fig la-c demonstrates the 
pattern of immunoperoxidase staining with \lt-3 antibody 
within the lesion, at its margin, and 3 mm from the edge of the 
clinically visible plaque. 
Within the plaque, \lt-3 antibody uniformly labels the cyto-
p lasm of the keratinocytes above the basal layer. Neither the 
basal layer nor the stratum corneum is stained. A similar 
pattern is seen at the border of the lesion. In the adjacent 
nonacanthotic epidermis, \lt-3 antibody staining is present out 
to the edge of the biopsy, at least 3 mm from the visible plaque. 
However, the number of labeled keratinocytes decreases, stain-
ing being lost first from the most superficial layers of the 
epidermis until it remains only in keratinocytes immediately 
above the basal layer. 
Lichen Planus-like Lesions 
The biopsy was taken from a flat, violaceous papule. The 
section shown in Fig le,f displays hypergranulosis, acanthosis, 
a heavy mononuclear dermal infiltrate, and is clearly stained 
by 'li-3 antibody. The pattern of 'li-3 antibody staining in this 
condition is interesting in that it includes the epidermal cell 
layer adjacent to the dermis in some regions and shows peri-
nuclear distribution. 
Acanthotic Epidermis Overlying Dermatofibroma 
Fig lg,h shows a dermatofibroma occupying almost the whole 
ofthe dermis, overlayed by acanthotic epidermis. \lt-3 antibody 
immunolabels keratinocytes in the lower half of the epidermis 
throughout the area of acanthosis (Fig. lg) . This dermal neo-
plasm is accompanied by minimal inflammatory infiltrate. The 
basal cells are heavily pigmented and the dusty granular ap-
pearance of the melanin could resemble w -3 antibody staining. 
Careful comparison of the immunoperoxidase-stained sections 
(Fig lg) with controls (Fig lh) indicated that, indeed, all the 
TABLE I. Occurrence of 1/;-3 antibody staining in cutaneous diseases by 
the immunoperoxidase method 
Psoriasis 
Squamous cell carcinoma 
Keratoacanthoma 
Condyloma acuminatum 
Irritated seborrheic keratosis 
Tape-stripped skin 
Blister injury 
Lichen planus-like lesion 
Pityriasis rubra pilaris 
Basal cell carcinoma 
Actinic porokeratosis 
Nontraumatized normal epidermis 
Lesion-free epidermis in psoriatics 
Epidermis overlying dermal lesions: 
Dermatofibroma 
Basal cell carcinoma 
Hemangioma 
1/;·3 Cases 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
10/10 
3/3 
1/1 
1/1 
1/ 1 
1/ 1 
1/ 1 
1/ 1 
1/ 1 
4/4 
1/1 
10/10 
6/6 
2/2 
4/4 
1/ 1 
Squamous Cell Carcinoma 
Fig li shows a well-differentiated squamous cell carcinoma 
with nests and prongs of abnormal squamous cells projecting 
downward into the dermis. Several rounded nests have concen-
tric layers of parakeratosis at their cores (keratin pearls). \lt-3 
antibody immunolabels most of the malignant squamous cells 
except the outermost cell layer and the parakeratotic cores. In 
companion hematoxylin and eosin-stained sections, many of 
the mitoses occur in the outermost layer of cells, but we have 
found a number of mitotic figures in the inner layers of the 
squamous cell nests which are stained by 'li-3 antibody. 
Condyloma Acuminatum 
One case has been studied to date, a patient who was a graft 
recipient receiving immunosuppressive therapy. Fig lj demon-
strates a large connective tissue core surmounted by an epider-
mis which shows papillomatosis and regular acanthosis. The 
granular layer is focally preserved. 'li-3 antibody stains the 
kerat inocytes above the basal layer, disappearing near the 
hyperkeratotic stratum corneum. 
DISCUSSION 
\lt-3 antigen (or a cross-reactive antigen) can be detected 
both in established psoriatic lesions as large as plaques and 
developing lesions as small as a 2-mm papule. It is also found 
in clinically "lesion-free" skin immediately adjacent to a plaque, 
which histologically shows changes suggestive of impending 
development of visible psoriasis. As a subcellular marker, \lt-3 
antigen can thus be identified before there is clinical evidence 
or unequivocal histologic findings of psoriasis. 
The occurrence of \lt-3 antigen in other dermatologic condi-
tions, however, shows no correlation with any simple histo-
pathologic feature or combination of features of psoriasis. In 
particular, it is not uniformly associated either with loss of the 
granular layer or epidermal hyperproliferation, two major char-
acteristics of psoriasis [26]. In our lichen planus-like lesion and 
condyloma acuminatum, for instance, ~-3 antibody staining is 
present together with the granular layer. With respect to ker-
atinocyte growth rate, lamellar ichthyosis is generally hyper-
proliferative [27] but, in the case we examined, showed no w-3 
antibody staining. By contrast, lichen planus, which generally 
shows a proliferation rate which is less than normal [28] , was 
stained by \lt-3 antibody. Expression of \lt -3 antigen by a cell, 
however, does not preclude mitosis. In squamous cell carci-
noma, we were able to detect mitoses within the region of cells 
stained with w-3 antibody. In addition, the intensity of staining 
by 'li-3 antibody shows no relationship to the density of inflam-
matory infiltrate. Although we have not obtained a \lt-3 anti-
body stained specimen with no inflammation at all, the dermis 
adjacent to the dermatofibroma described above shows minimal 
inflammation but the overlying epidermis is still stained by \lt-
3 antibody. In Darier's disease, we found no \lt-3 antibody 
staining, but an appreciable infiltrate. 
The staining of lesion -free psoriatic skin immediately adja-
cent to a psoriatic plaque shows two patterns. In a pinpoint 
lesion, staining diminishes rapidly with 0.5 mm of the visible 
margin of the lesion. In a well-established lesion, it persists for 
a number of millimeters beyond the lesion and is lost first from 
the most superficial layers, remaining in the immediately su-
prabasal layer for a considerable distance. The reason for the 
variation in these -It -3 antibody staining patterns is not known, 
but they are reminiscent of results obtained during wound 
healing experiments (unpublished results). Following epidermal 
102 STREFLlNG, KNAPP , AND MANSBRIDGE Vol. 84, No.2 
Feb. 1985 '11-3 STAINING OF PSORIASIS AND OTHER CUTANEOUS DISEASES 103 
injury, for instance by tape stripping, w-3 antibody staining 
appears within 24 h in a ll leve ls of the stratum spinosum, 
reaches a peak at 48 h, and t hen disappears first from the most 
superficial layers, finally leaving a single suprabasal layer 
stained. It is tempting to conclude t hat the abrupt disappear-
ance of w-3 ant igen in a pinpoint papule represents the induc-
tion of its expression in rap idly advancing lesions, while t he 
gradual loss from the more superficial regions of the spinous 
layer outside an establi shed plaque results from an attempt to 
repress w-3 antigen expression. 
The pattern of w-3 antibody staining fou nd in suprabasal 
maturing cells is retained in keratinocyte-derived tumors. Squa-
mous cell carcinomas a re immunolabeled and show sparing of 
the outermost layer of cells. Basal cell car cinomas are not 
labeled, presumably because they never express a maturation 
pathway involving '1'-3 antigen. 
The only pathologic condi tion in which we have fo und W- 3 
antiget, in the lowermost layer of the epidermis is lichen planus. 
The occurrence of -11 -3 antigen and, therefore, presumably 
maturing keratinocytes in this region supports t he proposal 
that the etiology of lichen planus involves a destruction of basal 
cells [29]. '1'-3 ant ibody staining in this case identifies ep ithelial 
cells expressing this keratinocyte maturation marker, migrating 
to fill the area of basal cell destruction. 
'It -3 antibody appears to recognize a unique feature of t he 
keratinocyte under certain pathologic conditions which is not 
detected by any other histologic or immunophenotyping 
method. It is thu a potentially va luab le addition to the ant i-
bodies and morphologic markers currently ava ilable for char-
acterizing ep itheli al t issues, e.g., antivimentin [30], the AE 
series [16], an t ibodies against basement membrane components 
[31,32], VM-1 [33], ant i-involucrin [34,35] and antifibronectin 
[36,37]. 
We wish to t ha nk Miss Jane Siguenza for her technical assistance 
a nd Mr. P hil Horne for the photography. 
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FIG 1. lmmunoperoxidase staining of selected dermatologic lesions by 'it -3 monoclonal ant ibody. a, This !00% parakeratotic zone of a 
psoriatic plaque shows uniform cytoplasm ic staining of the maturing keratinocytes in the epidermis. "'-3 stai ning disappea rs just beneath the 
parakeratotic scale. The basal ce ll layer is not stained (hematoxylin, X 100). b, T he approx imate histologic boundary between t he clinically 
visible edge of a psoriatic plaque and the immediately adjacent "clinically les ion-free skin " is demarcated by a vertical arrow. In this histologic 
border zone, the intensity of '11 -3 staining progressively diminishes from left to right (visible plaque--> "lesion-free skin"). Concurrently, t here is 
a lso a rapid loss of 'it -3 positivity beginning with the most superficial acanthocytes and progressing downward to the midportion of t he stratum 
malpighii (hematoxylin, X 100). c, Three millimeters from the clinically visible edge of the psoriatic plaque, there is a patchy loss of the gra nular 
layer accompan ied by mild acanthosis. "' -3 staining is now perceptible in on ly a few layers of keratinocytes immediately above the basal cell 
layer (hematoxylin, X 100). d, '11-3 staining of a pinpoint psoriatic papule (2 mm) is simila r to that seen in a psoriatic plaque (a). There is sparing 
of the basal ce ll layer and rapid loss of '1'-3 positivi ty in t he immediately adjacent (0.5 mm) epidermis (hematoxylin, x 100). e and(, Lichen 
p lanus-like lesion. The pattern of '11 -3 staining is both cytopla mic and perinuclear. Note the zone of hypergranulosis (top, e) and staining of the 
lowermost ce ll layer of t he epidermis where active destruction is occurring (hematoxylin, x 290). g and h, Acanthosis and increased pigmentation 
of the basal ce ll layer induced by an underlying dermatofibroma. g, stained with 'l' -3 a ntibody; h, co ntro l without '1
1
-antibody. "'-3 stai ning is 
present uniformly through the lower half of t he t hickened stratum malpighii, but not in the pigmented basa l ce ll layer (compare control section 
h) (hematoxylin , x 100). i, A well-differentiated squamous cell carci noma showing \f1 -3 immunolabeling in the epidermis and downwa rd 
infi lt rati ng nests and prongs. The keratin pearls and t he outer cell layer are not stained (hematoxylin, x 100). j, A representative frond from a 
condyloma acuminatum shows uniform cytoplasmic staining by 'it -3 antibody. \)1 -3 staining diminishes near the parakeratotic surface a nd is 
absent in the basal ce ll layer (hematoxylin , X 100). 
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